A PHASE III, MULTICENTER, RANDOMIZED, OPEN&#8209;LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLA&#8209;R&#8209;CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA

GO44145

Comprehensive Cancer Center Mainfranken

Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)

Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)

Phase III

Herr Prof. Dr.  Max Stanley Topp

Herr Dr. Johannes Düll

Medizinische Klinik II, Schwerpunkt Hämatologie/Onkologie

Universitätsklinikum Würzburg

Erstlinie

Therapeutisch